Castle BiosciencesFRA:086 +0.97%60 EV-to-FCF is 123.82 as of Jul. 07, 2026, which is 2347% above its 10-year median of 5.06. GuruFocus rates FRA:086 with a GF Score™ of 60/100 and a GF Value™ of €24.10 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 88.78% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Castle Biosciences's Enterprise Value is €447.2 Mil.
Castle Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €3.6 Mil. Therefore, Castle Biosciences's EV-to-FCF for today is 123.82.
The historical rank and industry rank for Castle Biosciences's EV-to-FCF or its related term are showing as below:
FRA:086'
s EV-to-FCF Range Over the Past 10 Years
Min: -324.42 Med: 5.06 Max: 958.93
Current: 112.06
During the past 9 years, the highest EV-to-FCF of Castle Biosciences was 958.93. The lowest was -324.42. And the median was 5.06.
FRA:086's EV-to-FCF is ranked worse than 88.78% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.975
vs FRA:086: 112.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Castle Biosciences's PE Ratio (TTM) for today is calculated as:
Castle Biosciences's share price for today is €20.80.
Castle Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.379.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Castle Biosciences EV-to-FCF Related Terms
Castle Biosciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Castle Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's EV-to-FCF falls into.
Castle Biosciences's current Enterprise Value is €447.2 Mil.
Castle Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (FRA:086) has a EV-to-FCF of 123.82 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Castle Biosciences and its competitors. This is 2347% above median its historical median of 5.06. According to the industry distribution chart, Castle Biosciences ranks #87 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 88.8%.
Is Castle Biosciences' EV-to-FCF too high?
Castle Biosciences' current EV-to-FCF of 123.82 is 2347% above median its 10-year median of 5.06. The Medical Diagnostics & Research industry median EV-to-FCF is 22.98. Castle Biosciences' value of 123.82 is 438.9% above this industry median. Based on the distribution chart, Castle Biosciences ranks #87 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Castle Biosciences has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' EV-to-FCF compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #87 out of 98 companies for EV-to-FCF. This places Castle Biosciences in the lower half of its industry. The industry median EV-to-FCF is 22.98. Castle Biosciences' value of 123.82 is 438.9% above this benchmark. While the company's 10-year median is 5.06 vs. the industry median of 22.98, Castle Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.98, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Castle Biosciences's current EV-to-FCF of 123.82 is 438.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Castle Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Castle Biosciences's current EV-to-FCF is 123.82, which is 2347% above median its own 10-year median of 5.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (FRA:086) is currently considered Modestly Undervalued. The stock's GF Value™ is €24.10, compared to a current price of €20.80 — trading 13.7% below its estimated fair value. The current EV-to-FCF is 123.82, which is 2347% above median its 10-year median of 5.06 and 438.9% above the Medical Diagnostics & Research industry median of 22.98. Castle Biosciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Castle Biosciences (FRA:086), the current EV-to-FCF is 123.82 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (FRA:086) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of €20.80 is trading 13.7% below its estimated GF Value™ of €24.10.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for FRA:086:
EV-to-FCF: 123.82 (2347% above median its 10-year median of 5.06)
GF Value™: €24.10 vs. price of €20.80 (13.7% below fair value)
Industry Position: 438.9% above the Medical Diagnostics & Research median (#87 of 98)
No single metric tells the full story. See the FRA:086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
60GF Score
Get the complete analysis for FRA:086
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:086 has been successfully added to your 
